Rozlytrek.com

Keyword Suggestion

Rozlytrek

Rozlytrek 200 mg

Rozlytrek clinical trial

Rozlytrek chpl

Rozlytrek ema

Rozlytrek entrectinib

Rozlytrek smpc

Rozlytrek package insert

Rozlytrek fda label

Rozlytrek fda

Rozlytrek rcp

Rozlytrek side effects

Rozlytrek cost

Rozlytrek sales

Domain Informations

Whois Informations
Top 10 Domain Provider

Rozlytrek.com lookup results from whois.safenames.net server:

Network

Owner

Abuse

Technical support

Domain Provider	Number Of Domains
godaddy.com	286730
namecheap.com	101387
networksolutions.com	69118
tucows.com	52617
publicdomainregistry.com	39120
whois.godaddy.com	32793
enomdomains.com	23825
namesilo.com	21429
domains.google.com	21384
cloudflare.com	20573
gmo.jp	18110
name.com	17601
fastdomain.com	14708
register.com	13495
net.cn	12481
ionos.com	12416
ovh.com	12416
gandi.net	12305
registrar.amazon.com	12111

Host Informations

Check all domain's dns records

See Web Sites Hosted on 104.18.28.66

Fetching Web Sites Hosted

Site Inspections

Port Scanner (IP: 104.18.28.66)

› Ftp: 21

› Ssh: 22

› Telnet: 23

› Smtp: 25

› Dns: 53

› Http: 80

› Pop3: 110

› Portmapper, rpcbind: 111

› Microsoft RPC services: 135

› Netbios: 139

› Imap: 143

› Ldap: 389

› Https: 443

› SMB directly over IP: 445

› Msa-outlook: 587

› IIS, NFS, or listener RFS remote_file_sharing: 1025

› Lotus notes: 1352

› Sql server: 1433

› Point-to-point tunnelling protocol: 1723

› My sql: 3306

› Remote desktop: 3389

› Session Initiation Protocol (SIP): 5060

› Virtual Network Computer display: 5900

› X Window server: 6001

› Webcache: 8080

Spam Check (IP: 104.18.28.66)

› Dnsbl-1.uceprotect.net:

› Dnsbl-2.uceprotect.net:

› Dnsbl-3.uceprotect.net:

› Dnsbl.dronebl.org:

› Dnsbl.sorbs.net:

› Spam.dnsbl.sorbs.net:

› Bl.spamcop.net:

› Recent.dnsbl.sorbs.net:

› All.spamrats.com:

› B.barracudacentral.org:

› Bl.blocklist.de:

› Bl.emailbasura.org:

› Bl.mailspike.org:

› Bl.spamcop.net:

› Cblplus.anti-spam.org.cn:

› Dnsbl.anticaptcha.net:

› Ip.v4bl.org:

› Fnrbl.fast.net:

› Dnsrbl.swinog.ch:

› Mail-abuse.blacklist.jippg.org:

› Singlebl.spamgrouper.com:

› Spam.abuse.ch:

› Spamsources.fabel.dk:

› Virbl.dnsbl.bit.nl:

› Cbl.abuseat.org:

› Dnsbl.justspam.org:

› Zen.spamhaus.org:

Email address with rozlytrek.com

Found 0 emails of this domain

Recent Searched Sites

› Tischlerbise.com (26 seconds ago) / US

› Services.cro.ie (26 seconds ago) / US

› Dinamika-avia.com (35 seconds ago) / RU

› Arweave.news (32 seconds ago) / US

› Ebony-fish-g3mgbw.mystrikingly.com (31 seconds ago) / US

› Zelenstroy.online (33 seconds ago) / RU

› Rozlytrek.com (0 seconds ago) / US

› Unicorns-tech.com (44 seconds ago) / US

› Juegosdefriv20.com (4 seconds ago) / US

› Lamptetias.com (18 seconds ago) / CN

› Otoku-pc.com (16 seconds ago) / JP

› Filmxy.online (21 seconds ago) / US

› Parsonsandnardelli.com (17 seconds ago) / US

› Gazeteipekyol.com (26 seconds ago) / US

› Vipih.com (15 seconds ago) / CA

› Imgsen.com (8 seconds ago) / NL

› Castrovilletx.gov (8 seconds ago) / US

› Torrent5.net (41 seconds ago) / US

› 4sharpcorners.com (7 seconds ago) / US

› Bluebellatlenoirmills.com (1 seconds ago) / US

List of our tools

Emails by domain

Mobile Friendly Check

Page Speed Check

DNS Lookup

Ports Scan

Sites on host

Sitemap Generator

Websites Listing

We found Websites Listing below when search with rozlytrek.com on Search Engine

ROZLYTREK Distribution | ROZLYTREK Access Solutions

You can work with your preferred SP or contact ROZLYTREK Access Solutions to learn which SP the patient’s health insurance plan requires. Distributors for Federal Accounts. Distributor Telephone Fax Web Orders; ASD Healthcare (a Division of AmerisourceBergen Specialty Group) 800-746-6273. 800-547-9413: www.asdhealthcare.com : Cardinal Health Specialty …

Genentech-access.com

Rozlytrek gegen Krebs - ARZNEI-NEWS

2020-08-03 · Rozlytrek ließ die Tumoren bei mehr als der Hälfte der Menschen mit NTRK-fusionspositiven, lokal fortgeschrittenen oder metastasierten soliden Tumoren (Gesamtansprechrate [ORR]=63,5%; N=74) schrumpfen, und objektive Ansprechraten wurden bei 14 Tumorarten beobachtet (mediane Dauer des Ansprechens [DoR]=12,9 Monate [9,3 Monate …

Arznei-news.de

Rozlytrek, Roche’s first tumour-agnostic therapy, approved ...

2020-08-03 · Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive, locally advanced or metastatic solid tumours (overall response rate [ORR]=63.5%; N=74), and objective responses were observed across 14 tumour types (median duration of response [DoR]=12.9 months [9.3 months – not reached], N=21 out of 47 patients defined by ORR). 1 In …

Ca.finance.yahoo.com

Roche - Doing now what patients need next

2019-08-16 · Roche - Doing now what patients need next

Roche.com

Rozlytrek® (entrectinib) | Roche.nl

Rozlytrek (entrectinib) behoort tot een nieuwe klasse medicijnen, de tropomyosinereceptorkinase (TRK)-remmers. Dit geneesmiddel kan worden ingezet bij solide tumoren met specifieke afwijkingen in het NTRK-gen, zogenoemde genfusies. NTRK-genfusies leiden tot TRK-fusie-eiwitten, die op hun beurt weer kunnen leiden tot overleving en proliferatie van tumorcellen. …

Roche.nl

Rozlytrek - Entrectinib: Scheda Tecnica del Farmaco ...

2021-07-17 · Rozlytrek 100 mg capsule rigide Rozlytrek 200 mg capsule rigide . 02.0 Composizione qualitativa e quantitativa. Indice. Rozlytrek 100 mg capsule rigide. Ogni capsula rigida contiene 100 mg di entrectinib. Eccipienti con effetti noti. Ogni capsula rigida contiene 65 mg di lattosio. Rozlytrek 200 mg capsule rigide Ogni capsula rigida contiene 200 ...

Torrinomedica.it

Rozlytrek 100 mg Hartkapseln Rozlytrek 200 mg ... - Roche

Rozlytrek bestätigt werden (siehe Abschnitt 5.1). ROS1-positives nicht-kleinzelliges Lungenkarzinom Ein validierter Test ist für die Auswahl der Patienten mit ROS1-positivem NSCLC erforderlich. Ein ROS1-positiver Status muss vor Einleitung der Therapie mit Rozlytrek bestätigt werden (siehe Abschnitt 5.1). Dosierung Erwachsene Die empfohlene Dosis bei Erwachsenen …

Roche.at

Rozlytrek ® 羅思克 - roche.com.tw

Rozlytrek 適用於治療ROS1陽性之局部晚期或轉移性非小細胞肺癌的成人病人 . NTRK基因融合陽性之實體腫瘤. Rozlytrek 適用於治療NTRK基因融合陽性之實體腫瘤的成人病人，並應符合以下條件: 具NTRK基因融合且無已知的後天阻抗性突變(acquired resistance mutation)。為轉移性實體腫瘤，或手術切除極可能造成嚴重 ...

Roche.com.tw

Rozlytrek Studies Show Durable Responses in Patients With ...

2022-02-16 · Rozlytrek's success in crossing the blood-brain barrier may help differentiate it from other pan-tumor TRK inhibitors, including its main market competitor Bayer's Vitrakvi (larotrectinib). Vitrakvi was the first TRK inhibitor approved in the US in 2018 for patients with refractory solid tumors with NTRK gene fusions, who are out of treatment options.

Precisiononcologynews.com

Domains Expiration Date Updated

Site	Provider	Expiration Date
pornmature.one	namecheap.com	-2 Years, -81 Days
a-b-cpr.com	networksolutions.com	3 Years, 11 Days
kirbygladstein.com	tucows.com	-1 Years, -350 Days
achziv.info	enom.com	-2 Years, -89 Days
photiouestates.com	register.com	-1 Years, -342 Days
vivatopday.com	ukraine.com.ua	-2 Years, -182 Days
isabellauction.com	godaddy.com	-1 Years, -234 Days
nabakari.com	gmo.jp	232 Days
ethone.cc	namecheap.com	-2 Years, -83 Days
pathlock.com	gocanadadomains.com	-2 Years, -4 Days

Browser All